{
    "abstract": "Patients with cutaneous melanoma stage I/IIA disease are currently not eligible for adjuvant therapy, despite their risk for relapses and death. This study validates the ability of a model combining clinicopathologic factors with gene expression profiling (CP-GEP) to identify patients at high risk for disease recurrence in stage I/II and subgroup stage I/IIA.\n543 patients with stage I/II primary cutaneous melanoma from the University of Tuebingen diagnosed between 2000 and 2017 were analysed. All patients received sentinel lymph node biopsy (SLNB). Analysis was conducted for a separate group of 80 patients who did not undergo SLNB.\nCP-GEP stratified 424 stage I/IIA patients (78% of the cohort) according to their risk for recurrence, with five-year relapse-free survival (RFS) rates of 77.8% and 93% for CP-GEP high risk (195 patients) and low risk (229 patients), respectively, and hazard ratio of 3.53 (p-value <0.001). In patients who did not receive SLNB biopsy, CP-GEP captured 6 out of 7 relapses.\nCP-GEP can be used to identify primary cutaneous melanoma patients with a high risk for disease recurrence - especially for stage I/IIA, who are considered low risk by AJCC 8th. These patients may benefit from adjuvant therapy. Also, in the future, when SLNB may become irrelevant, CP-GEP may serve as a risk stratification tool.",
    "authors": [
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany; Cluster of Excellence IFIT (EXC 2180), Tuebingen, Germany. Electronic address: teresa.amaral@med.uni-tuebingen.de.",
            "firstname": "Teresa",
            "initials": "T",
            "lastname": "Amaral"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany; Cluster of Excellence IFIT (EXC 2180), Tuebingen, Germany.",
            "firstname": "Tobias",
            "initials": "T",
            "lastname": "Sinnberg"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany.",
            "firstname": "Eftychia",
            "initials": "E",
            "lastname": "Chatziioannou"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany; Cluster of Excellence IFIT (EXC 2180), Tuebingen, Germany.",
            "firstname": "Heike",
            "initials": "H",
            "lastname": "Niessner"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany.",
            "firstname": "Ulrike",
            "initials": "U",
            "lastname": "Leiter"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany.",
            "firstname": "Ulrike",
            "initials": "U",
            "lastname": "Keim"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany.",
            "firstname": "Andrea",
            "initials": "A",
            "lastname": "Forschner"
        },
        {
            "affiliation": "SkylineDx BV, Rotterdam, the Netherlands.",
            "firstname": "Jvalini",
            "initials": "J",
            "lastname": "Dwarkasing"
        },
        {
            "affiliation": "SkylineDx BV, Rotterdam, the Netherlands.",
            "firstname": "F\u00e9licia",
            "initials": "F",
            "lastname": "Tjien-Fooh"
        },
        {
            "affiliation": "SkylineDx BV, Rotterdam, the Netherlands.",
            "firstname": "Renske",
            "initials": "R",
            "lastname": "Wever"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany.",
            "firstname": "Lukas",
            "initials": "L",
            "lastname": "Flatz"
        },
        {
            "affiliation": "SkylineDx BV, Rotterdam, the Netherlands; Comprehensive Cancer Center M\u00fcnchen, Technical University Munich & Ludwig Maximiliaan University Munich, Germany; UMC Utrecht, the Netherlands.",
            "firstname": "Alexander",
            "initials": "A",
            "lastname": "Eggermont"
        },
        {
            "affiliation": "Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany.",
            "firstname": "Stephan",
            "initials": "S",
            "lastname": "Forchhammer"
        }
    ],
    "conclusions": "CP-GEP can be used to identify primary cutaneous melanoma patients with a high risk for disease recurrence - especially for stage I/IIA, who are considered low risk by AJCC 8th. These patients may benefit from adjuvant therapy. Also, in the future, when SLNB may become irrelevant, CP-GEP may serve as a risk stratification tool.",
    "copyrights": "Copyright \u00a9 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.",
    "doi": "10.1016/j.ejca.2022.12.021",
    "journal": "European journal of cancer (Oxford, England : 1990)",
    "keywords": [
        "Adjuvant therapy",
        "Biomarker",
        "CP-GEP",
        "Risk stratification",
        "Stage I/II melanoma"
    ],
    "methods": null,
    "publication_date": "2023-02-05",
    "pubmed_id": "36739215",
    "results": "CP-GEP stratified 424 stage I/IIA patients (78% of the cohort) according to their risk for recurrence, with five-year relapse-free survival (RFS) rates of 77.8% and 93% for CP-GEP high risk (195 patients) and low risk (229 patients), respectively, and hazard ratio of 3.53 (p-value <0.001). In patients who did not receive SLNB biopsy, CP-GEP captured 6 out of 7 relapses.",
    "title": "Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).",
    "xml": "<Element 'PubmedArticle' at 0x788502b38b80>"
}